Hence, cGAS-STING inhibition has the potential to decrease obesity-associated inflammation, type 2 diabetes mellitus (T2DM), NASH/NAFLD, defective wound healing, and angiogenesis. Here, STING1 is linked to metabolic dysfunction-associated steatotic liver disease.